Regenerative medicine therapy: adipose derived extracellular vesicles in viral myocarditis by Gorelov, David et al.
Regenerative medicine therapy: adipose derived extracellular vesicles in 
viral myocarditis
David Gorelov1,2, Katelyn A. Bruno, PhD1,2,3, Damian N. Di Florio1,2, Gary R. Salomon1,2, Angita Jain1,2, Nick E. Saikaili1,2, Danielle J. Beetler1,2, Swikriti Shrestha1,2, Ming Tian4,5, Joy 
Wolfram, PhD4,5, DeLisa Fairweather, PhD1,2,3
1Department of Clinical and Translational Research, 2Department of Cardiovascular Medicine, 3Department of Immunology, 4Department of Transplantation Medicine, 5Department of 
Physiology and Biomedical Engineering, Mayo Clinic , Jacksonville, Florida, USA
Conclusions
• AEV treatment decreases myocarditis severity (decreases % inflammation in the heart,
increases body weight, and decreases calcification)
• AEV decreases immune cell populations in the heart (total immune cells, neutrophils, mast
cells, and dendritic cells, macrophages and T cells
• AEV treated mice have higher expression of CR1, the primary regulator of the complement
system. AEV also decreases expression of main complement cascade components
• AEVs decrease proinflammatory and profibrotic TLR4 and caspase-1
• AEVs altered hormone expression, specifically ERα and ERRγ in the heart of mice
Future Studies
• Determine whether AEV treatment can reduce or prevent DCM and chronic heart failure if
given during myocarditis- a clinically relevant time-point
• Perform flow cytometry to better characterize immune cell populations
• Determine the internal and external composition of AEVs
• Compare ip to iv routes of administration
• Investigate anti-inflammatory drug loaded AEVs effect on myocarditis and DCM
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Objective: Myocarditis, inflammation of the heart muscle, is an autoimmune
heart disease that can be caused by viruses, bacteria and toxins.
Myocarditis can lead to dilated cardiomyopathy (DCM) and heart failure.
Currently there are no disease-specific therapies for treating myocarditis or
preventing progression to DCM. Adipose Extracellular Vesicles (AEVs) are
lipid bilayer nanoparticles that are released into the outside environment of
adipocytes and provide promising regenerative potential for inflammatory
diseases like myocarditis.
Methods: Lipoaspirate was obtained from women and men and AEVs
isolated from the lipoaspirate using tangential flow filtration. We injected wild
type male BALB/c mice with 250uL AEVs (1x10^10 EV/mL) intraperitoneally
or sucrose control on day -1, 0, 1 with viral infection on day 0. Mice were
harvested on day 10 post infection at the peak of myocarditis.
Results: We found that male mice treated with AEVs from a female patient
had a significantly higher body weight (p=0.0003), less calcification in the gut
(p=0.001) and less myocardial inflammation (p=0.007) than controls. Mouse
hearts analyzed by qRT-PCR revealed that AEV treated mice had
significantly lower relative gene expression of cell markers for total immune
cells (CD45, p=0.002), macrophages (CD11b, p=0.002, F4/80, p=0.0004);
specifically M2 macrophages (Chi313, p=0.003), as well as CD3+ (p=0.007)
and CD4+ T cells (p=0.01) than controls. Additionally, we found that mice
treated with AEVs from a male patient also had significantly less myocardial
inflammation (p=0.01).
Conclusion: AEVs could provide an innovative therapy to reduce cardiac
inflammation and decrease the risk of developing DCM following myocarditis.
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Schematic 1. Procedure for obtaining AEVs by
processing human lipoaspirate.
Schematic 2: Schematic
illustrating the difference
between dead-end filtration
and tangential flow
filtration (TFF).
Figure 10. Lipo-NPs (AEVS) from two different 
women and one man decrease CVB3 myocarditis 
when given to male BALB/c mice. 
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Figure 4. AEV decreased disease severity. AEV treatment reduced calcification (left)
and increased body weight (right)- both measures of improved disease.
Figure 5. AEV treatment does not significantly alter CVB3 viral genome number in the
heart. Y-axis is log10 scale; RGE determined using qRT-PCR. These findings suggest that
reduced cardiac inflammation is not related to reduced viral levels in the heart.
Figure 1. Disease progression for viral myocarditis in animal model
Figure 3. AEV treated mice have significantly reduced inflammation
compared to sucrose treated controls. Inflammation (%) scored using
H&E stain and eye piece grid normalized to the size of the heart.
Figure 6. AEV treatment reduces immune cell markers compared to control. AEVs
decrease total immune cells (CD45+), Total T cells/T helper cells (CD3), CD11b (neutrophils,
macrophages, mast cells and dendritic cells), and F4/80 (activated macrophages).
Figure 7. Hearts of AEV treated mice have decreased expression of TLR4 (left) and caspase-1
(right), which increase inflammation and remodeling in the heart.
Figure 8. AEV treated mice have higher expression of the complement inhibitor, CR1
which lowers expression of activated complement pathway genes C3, C3aR1, and C4b
and reduces inflammation.
Control AEV
Figure 2. Study design for AEV treated mice during myocarditis.
Figure 9. AEVs altered hormone expression in the heart of mice. 
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